Michael Rogers

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Anatomy

Physiology

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Guenther Andreas; Gordon Sharon; Tiemann Markus; Burger Renate; Bakker Frank; Green Jonathan R; Baum Wolfgang; Roelofs Anke J; Rogers Michael J; Gramatzki Martin
The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.
Whyte Lauren S; Ryberg Erik; Sims Natalie A; Ridge Susan A; Mackie Ken; Greasley Peter J; Ross Ruth A; Rogers Michael J
The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo.
Räikkönen Johanna; Crockett Julie C; Rogers Michael J; Mönkkönen Hannu; Auriola Seppo; Mönkkönen Jukka
Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Michael Rogers (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2010: Guenther Andreas; Gordon Sharon; Tiemann Markus; Burger Renate; Bakker Frank; Green Jonathan R; Baum Wolfgang; Roelofs Anke J; Rogers Michael J; Gramatzki Martin
The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.
International journal of cancer. Journal international du cancer 2010;126(1):239-46.
2009: Whyte Lauren S; Ryberg Erik; Sims Natalie A; Ridge Susan A; Mackie Ken; Greasley Peter J; Ross Ruth A; Rogers Michael J
The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(38):16511-6.
2009: Räikkönen Johanna; Crockett Julie C; Rogers Michael J; Mönkkönen Hannu; Auriola Seppo; Mönkkönen Jukka
Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro.
British journal of pharmacology 2009;157(3):427-35.
2009: Hirbe Angela C; Roelofs Anke J; Floyd Desiree H; Deng Hongju; Becker Stephanie N; Lanigan Lisa G; Apicelli Anthony J; Xu Zhiqiang; Prior Julie L; Eagleton Mark C; Piwnica-Worms David; Rogers Michael J; Weilbaecher Katherine
The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.
Bone 2009;44(5):908-16.
2009: Roelofs Anke J; Jauhiainen Marjo; Mönkkönen Hannu; Rogers Michael J; Mönkkönen Jukka; Thompson Keith
Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP.
British journal of haematology 2009;144(2):245-50.
2009: Sutherland Karen A; Rogers Helena L; Tosh Denise; Rogers Michael J
RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro.
Arthritis research & therapy 2009;11(2):R58.
2008: Guerrini Matteo M; Sobacchi Cristina; Cassani Barbara; Abinun Mario; Kilic Sara S; Pangrazio Alessandra; Moratto Daniele; Mazzolari Evelina; Clayton-Smith Jill; Orchard Paul; Coxon Fraser P; Helfrich Miep H; Crockett Julie C; Mellis David; Vellodi Ashok; Tezcan Ilhan; Notarangelo Luigi D; Rogers Michael J; Vezzoni Paolo; Villa Anna; Frattini Annalisa
Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations.
American journal of human genetics 2008;83(1):64-76.
2008: Russell R G G; Watts N B; Ebetino F H; Rogers M J
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2008;19(6):733-59.
2008: Coxon Fraser P; Thompson Keith; Roelofs Anke J; Ebetino F Hal; Rogers Michael J
Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Bone 2008;42(5):848-60.
2008: Dunford James E; Kwaasi Aaron A; Rogers Michael J; Barnett Bobby L; Ebetino Frank H; Russell R Graham G; Oppermann Udo; Kavanagh Kathryn L
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
Journal of medicinal chemistry 2008;51(7):2187-95.
2007: Crockett Julie C; Schütze Norbert; Tosh Denise; Jatzke Susanne; Duthie Angela; Jakob Franz; Rogers Michael J
The matricellular protein CYR61 inhibits osteoclastogenesis by a mechanism independent of alphavbeta3 and alphavbeta5.
Endocrinology 2007;148(12):5761-8.
2007: Russell R Graham G; Xia Zhidao; Dunford James E; Oppermann Udo; Kwaasi Aaron; Hulley Philippa A; Kavanagh Kathryn L; Triffitt James T; Lundy Mark W; Phipps Roger J; Barnett Bobby L; Coxon Fraser P; Rogers Michael J; Watts Nelson B; Ebetino Frank H
Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
Annals of the New York Academy of Sciences 2007;1117():209-57.
2007: Hughes Alun; Rogers Michael J; Idris Aymen I; Crockett Julie C
A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo.
Calcified tissue international 2007;81(5):403-13.
2007: Sobacchi Cristina; Frattini Annalisa; Guerrini Matteo M; Abinun Mario; Pangrazio Alessandra; Susani Lucia; Bredius Robbert; Mancini Grazia; Cant Andrew; Bishop Nick; Grabowski Peter; Del Fattore Andrea; Messina Chiara; Errigo Gabriella; Coxon Fraser P; Scott Debbie I; Teti Anna; Rogers Michael J; Vezzoni Paolo; Villa Anna; Helfrich Miep H
Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL.
Nature genetics 2007;39(8):960-2.
2007: Roelofs Anke J; Edwards Claire M; Russell R Graham G; Ebetino F Hal; Rogers Michael J; Hulley Philippa A
Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
The Journal of pharmacology and experimental therapeutics 2007;322(1):228-35.
2007: Van Wesenbeeck Liesbeth; Odgren Paul R; Coxon Fraser P; Frattini Annalisa; Moens Pierre; Perdu Bram; MacKay Carole A; Van Hul Els; Timmermans Jean-Pierre; Vanhoenacker Filip; Jacobs Ruben; Peruzzi Barbara; Teti Anna; Helfrich Miep H; Rogers Michael J; Villa Anna; Van Hul Wim
Involvement of PLEKHM1 in osteoclastic vesicular transport and osteopetrosis in incisors absent rats and humans.
The Journal of clinical investigation 2007;117(4):919-30.
2007: Taylor A; Rogers M J; Tosh D; Coxon F P
A novel method for efficient generation of transfected human osteoclasts.
Calcified tissue international 2007;80(2):132-6.
2006: Roelofs Anke J; Thompson Keith; Gordon Sharon; Rogers Michael J
Molecular mechanisms of action of bisphosphonates: current status.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 2):6222s-6230s.
2006: Coxon Fraser P; Thompson Keith; Rogers Michael J
Recent advances in understanding the mechanism of action of bisphosphonates.
Current opinion in pharmacology 2006;6(3):307-12.
2006: Dunford James E; Rogers Michael J; Ebetino Frank H; Phipps Roger J; Coxon Fraser P
Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2006;21(5):684-94.
2006: Kavanagh Kathryn L; Guo Kunde; Dunford James E; Wu Xiaoqiu; Knapp Stefan; Ebetino Frank H; Rogers Michael J; Russell R Graham G; Oppermann Udo
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(20):7829-34.
2006: Thompson Keith; Rogers Michael J; Coxon Fraser P; Crockett Julie C
Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis.
Molecular pharmacology 2006;69(5):1624-32.
2006: Thompson Keith; Rojas-Navea Javier; Rogers Michael J
Alkylamines cause Vgamma9Vdelta2 T-cell activation and proliferation by inhibiting the mevalonate pathway.
Blood 2006;107(2):651-4.
2005: Coxon Fraser P; Ebetino Frank H; Mules Emilie H; Seabra Miguel C; McKenna Charles E; Rogers Michael J
Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.
Bone 2005;37(3):349-58.
2005: Luckman Steven P; Hughes David E; Coxon Fraser P; Russell Graham G; Rogers Michael J
JBMR anniversary classic. Nitrogen-containing biophosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Originally published in Volume 7, number 4, pp 581-9 (1998).
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2005;20(7):1265-74.
2004: Rogers M J
From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates.
Calcified tissue international 2004;75(6):451-61.
2004: Thompson Keith; Rogers Michael J
Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2004;19(2):278-88.
2003: Frith Julie C; Rogers Michael J
Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2003;18(2):204-12.
2003: Staal Ada; Frith Julie C; French Michele H; Swartz Joann; Güngör Timur; Harrity Thomas W; Tamasi Joseph; Rogers Michael J; Feyen Jean H M
The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2003;18(1):88-96.
2003: Coxon F P; Rogers M J
The role of prenylated small GTP-binding proteins in the regulation of osteoclast function.
Calcified tissue international 2003;72(1):80-4.
2003: Rogers Michael J
New insights into the molecular mechanisms of action of bisphosphonates.
Current pharmaceutical design 2003;9(32):2643-58.
2003: Coxon Fraser P; Frith Julie C; Benford Helena L; Rogers Michael J
Isolation and purification of rabbit osteoclasts.
Methods in molecular medicine 2003;80():89-99.
2002: Gordon Sharon; Helfrich Miep H; Sati Hamdi I A; Greaves Michael; Ralston Stuart H; Culligan Dominic J; Soutar Richard L; Rogers Michael J
Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma.
British journal of haematology 2002;119(2):475-83.
2002: Thompson Keith; Dunford James E; Ebetino Frank H; Rogers Michael J
Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.
Biochemical and biophysical research communications 2002;290(2):869-73.
2001: Coxon F P; Helfrich M H; Larijani B; Muzylak M; Dunford J E; Marshall D; McKinnon A D; Nesbitt S A; Horton M A; Seabra M C; Ebetino F H; Rogers M J
Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages.
The Journal of biological chemistry 2001;276(51):48213-22.
2001: Mönkkönen H; Rogers M J; Makkonen N; Niva S; Auriola S; Mönkkönen J
The cellular uptake and metabolism of clodronate in RAW 264 macrophages.
Pharmaceutical research 2001;18(11):1550-5.
2001: Suri S; Mönkkönen J; Taskinen M; Pesonen J; Blank M A; Phipps R J; Rogers M J
Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity.
Bone 2001;29(4):336-43.
2001: Frith J C; Mönkkönen J; Auriola S; Mönkkönen H; Rogers M J
The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis.
Arthritis and rheumatism 2001;44(9):2201-10.
2001: Benford H L; McGowan N W; Helfrich M H; Nuttall M E; Rogers M J
Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro.
Bone 2001;28(5):465-73.
2001: Dunford J E; Thompson K; Coxon F P; Luckman S P; Hahn F M; Poulter C D; Ebetino F H; Rogers M J
Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
The Journal of pharmacology and experimental therapeutics 2001;296(2):235-42.
2000: Shipman C M; Vanderkerken K; Rogers M J; Lippitt J M; Asosingh K; Hughes D E; Van Camp B; Russell R G; Croucher P I
The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
British journal of haematology 2000;111(1):283-6.
2000: Coxon F P; Helfrich M H; Van't Hof R; Sebti S; Ralston S H; Hamilton A; Rogers M J
Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2000;15(8):1467-76.
2000: Rogers M J; Gordon S; Benford H L; Coxon F P; Luckman S P; Monkkonen J; Frith J C
Cellular and molecular mechanisms of action of bisphosphonates.
Cancer 2000;88(12 Suppl):2961-78.
2000: Mönkkönen H; Moilanen P; Mönkkönen J; Frith J C; Rogers M J; Auriola S
Analysis of an adenine nucleotide-containing metabolite of clodronate using ion pair high-performance liquid chromatography-electrospray ionisation mass spectrometry.
Journal of chromatography. B, Biomedical sciences and applications 2000;738(2):395-403.
2000: Shipman C M; Rogers M J; Vanderkerken K; Van Camp B; Graham R; Russell G; Croucher P I
Bisphosphonates--mechanisms of action in multiple myeloma.
Acta oncologica (Stockholm, Sweden) 2000;39(7):829-35.
1999: Russell R G; Rogers M J; Frith J C; Luckman S P; Coxon F P; Benford H L; Croucher P I; Shipman C; Fleisch H A
The pharmacology of bisphosphonates and new insights into their mechanisms of action.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1999;14 Suppl 2():53-65.
1999: Russell R G; Rogers M J
Bisphosphonates: from the laboratory to the clinic and back again.
Bone 1999;25(1):97-106.
1999: Benford H L; Frith J C; Auriola S; Mönkkönen J; Rogers M J
Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs.
Molecular pharmacology 1999;56(1):131-40.
1999: Rogers M J; Frith J C; Luckman S P; Coxon F P; Benford H L; Mönkkönen J; Auriola S; Chilton K M; Russell R G
Molecular mechanisms of action of bisphosphonates.
Bone 1999;24(5 Suppl):73S-79S.
1999: Makkonen N; Salminen A; Rogers M J; Frith J C; Urtti A; Azhayeva E; Mönkkönen J
Contrasting effects of alendronate and clodronate on RAW 264 macrophages: the role of a bisphosphonate metabolite.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 1999;8(2):109-18.
1999: Fisher J E; Rogers M J; Halasy J M; Luckman S P; Hughes D E; Masarachia P J; Wesolowski G; Russell R G; Rodan G A; Reszka A A
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(1):133-8.
1998: Shipman C M; Rogers M J; Apperley J F; Graham R; Russell G; Croucher P I
Anti-tumour activity of bisphosphonates in human myeloma cells.
Leukemia & lymphoma 1998;32(1-2):129-38.
1998: Shipman C M; Croucher P I; Russell R G; Helfrich M H; Rogers M J
The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.
Cancer research 1998;58(23):5294-7.
1998: Luckman S P; Coxon F P; Ebetino F H; Russell R G; Rogers M J
Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1998;13(11):1668-78.
1998: Coxon F P; Benford H L; Russell R G; Rogers M J
Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs.
Molecular pharmacology 1998;54(4):631-8.
1998: Luckman S P; Hughes D E; Coxon F P; Graham R; Russell G; Rogers M J
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1998;13(4):581-9.
1997: Auriola S; Frith J; Rogers M J; Koivuniemi A; Mönkkönen J
Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry.
Journal of chromatography. B, Biomedical sciences and applications 1997;704(1-2):187-95.
1997: Rogers M J; Watts D J; Russell R G
Overview of bisphosphonates.
Cancer 1997;80(8 Suppl):1652-60.
1997: Shipman C M; Rogers M J; Apperley J F; Russell R G; Croucher P I
Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.
British journal of haematology 1997;98(3):665-72.
1997: Frith J C; Mönkkönen J; Blackburn G M; Russell R G; Rogers M J
Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1997;12(9):1358-67.
1997: Rogers M J; Xiong X; Ji X; Mönkkönen J; Russell R G; Williamson M P; Ebetino F H; Watts D J
Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonate drugs is dependent on cellular uptake.
Pharmaceutical research 1997;14(5):625-30.
1996: Rogers M J; Chilton K M; Coxon F P; Lawry J; Smith M O; Suri S; Russell R G
Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1996;11(10):1482-91.
1996: Rogers M J; Brown R J; Hodkin V; Blackburn G M; Russell R G; Watts D J
Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes.
Biochemical and biophysical research communications 1996;224(3):863-9.
1995: Rogers M J; Xiong X; Brown R J; Watts D J; Russell R G; Bayless A V; Ebetino F H
Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae.
Molecular pharmacology 1995;47(2):398-402.
1994: Rogers M J; Ji X; Russell R G; Blackburn G M; Williamson M P; Bayless A V; Ebetino F H; Watts D J
Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum.
The Biochemical journal 1994;303 ( Pt 1)():303-11.
1994: Rogers M J; Watts D J; Russell R G; Ji X; Xiong X; Blackburn G M; Bayless A V; Ebetino F H
Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold Dictyostelium discoideum.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1994;9(7):1029-39.
1992: Rogers M J; Russell R G; Blackburn G M; Williamson M P; Watts D J
Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum.
Biochemical and biophysical research communications 1992;189(1):414-23.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Michael Rogers

Research Profile (preview)

Chemicals & Drugs

Anatomy

Physiology

Living Beings

Concepts & Ideas

Disorders

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Michael Rogers (preview)

All Publications